TY - JOUR
T1 - Adiponectin protects against incident hypertension independent of body fat distribution
T2 - observations from the Dallas Heart Study
AU - Peri-Okonny, Poghni A.
AU - Ayers, Colby
AU - Maalouf, Naim M
AU - Das, Sandeep R
AU - de Lemos, James A
AU - Berry, Jarett D
AU - Turer, Aslan T
AU - Neeland, Ian J
AU - Scherer, Philipp E
AU - Vongpatanasin, Wanpen
N1 - Publisher Copyright:
Copyright © 2016 John Wiley & Sons, Ltd.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Background: Excess adipose tissue has been implicated in the pathogenesis of insulin resistance and atherosclerosis and is a key risk factor for blood pressure (BP) elevation. However, circulating levels of adiponectin, a protein produced by adipose tissue and widely implicated in the pathogenesis of insulin resistance and atherosclerosis, are inversely proportional to adiposity. The relationship between adiponectin and incident hypertension has not been determined in the general US population. Methods: Normotensive participants (n = 1233) enrolled in the Dallas Heart Study, a multiethnic, probability-based population sample of Dallas County adults were followed for median of 7 years. Retroperitoneal, intraperitoneal, visceral, and subcutaneous adipose tissue were measured at baseline by magnetic resonance imaging. Liver fat content was measured by 1H-magnetic resonance spectroscopy. Relative risk regression was used to determine the association of adiponectin with incident hypertension after adjustment for age, race, sex, BMI, smoking, diabetes, baseline systolic BP, total cholesterol, and regional fat depot. Results: Of the 1233 study participants (median age 40 years, 40% black, and 56% women), 391 (32%) had developed hypertension over a median follow-up of 7 years. Adiponectin levels were associated with reduced risk of incident hypertension (RR 0.81, 95% CI [0.68-0.96]) in the fully adjusted model, which included liver fat. Similar results were observed after adjustment for subcutaneous or visceral fat depots when tested individually or simultaneously in the model. Conclusion: Our study suggested a protective role of adiponectin against incident hypertension independent of body fat distribution.
AB - Background: Excess adipose tissue has been implicated in the pathogenesis of insulin resistance and atherosclerosis and is a key risk factor for blood pressure (BP) elevation. However, circulating levels of adiponectin, a protein produced by adipose tissue and widely implicated in the pathogenesis of insulin resistance and atherosclerosis, are inversely proportional to adiposity. The relationship between adiponectin and incident hypertension has not been determined in the general US population. Methods: Normotensive participants (n = 1233) enrolled in the Dallas Heart Study, a multiethnic, probability-based population sample of Dallas County adults were followed for median of 7 years. Retroperitoneal, intraperitoneal, visceral, and subcutaneous adipose tissue were measured at baseline by magnetic resonance imaging. Liver fat content was measured by 1H-magnetic resonance spectroscopy. Relative risk regression was used to determine the association of adiponectin with incident hypertension after adjustment for age, race, sex, BMI, smoking, diabetes, baseline systolic BP, total cholesterol, and regional fat depot. Results: Of the 1233 study participants (median age 40 years, 40% black, and 56% women), 391 (32%) had developed hypertension over a median follow-up of 7 years. Adiponectin levels were associated with reduced risk of incident hypertension (RR 0.81, 95% CI [0.68-0.96]) in the fully adjusted model, which included liver fat. Similar results were observed after adjustment for subcutaneous or visceral fat depots when tested individually or simultaneously in the model. Conclusion: Our study suggested a protective role of adiponectin against incident hypertension independent of body fat distribution.
KW - Adiponectin
KW - fat
KW - hypertension
KW - leptin
KW - subcutaneous adipose tissue
KW - visceral adipose tissue
UR - http://www.scopus.com/inward/record.url?scp=84982230793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982230793&partnerID=8YFLogxK
U2 - 10.1002/dmrr.2840
DO - 10.1002/dmrr.2840
M3 - Article
C2 - 27455039
AN - SCOPUS:84982230793
SN - 1520-7552
VL - 33
JO - Diabetes/Metabolism Research and Reviews
JF - Diabetes/Metabolism Research and Reviews
IS - 2
M1 - e2840
ER -